At long last, there might be a COVID treatment leftists won't denigrate: But how much will it cost?

American Thinker ^ | 09/13/2021 | Pinrae Jonsson

[SeekAndFind]

One of the most peculiar things about COVID in America is that the powers that be — in politics, media, and medicine — have been hostile to the possibility of treating COVID.  Since the virus emerged, people have been told there's nothing that can be done to treat COVID until they're near death, at which point...there's nothing that can be done to treat COVID.  These same actors have hysterically opposed both the hydroxychloroquine cocktail and ivermectin.  However, that resistance to early intervention may change now that Pfizer has a COVID-19 therapeutic antiviral protease inhibitor called PF-07321332.

PF-07321332 entered its phase two and three trials in August 2021.  The treatment will be administered orally, although another version, called PF-07304814, is administered through an IV drip.  According to Pfizer:

We believe that, if successful and authorized or approved, these investigational therapies could provide end-to-end treatment options for COVID-19 patients, including those exposed to the virus, those with diagnosed infections treated in the outpatient setting, and those hospitalized with moderate to severe infection.

Antiviral medications operate by interfering with a virus's ability to replicate in the body.  If the medication is given early enough in the illness's progress, the infection will be weak.  Protease inhibitors and other antivirals have been around for a long time for treating various illnesses, but they've only had off-label use in treating COVID cases.  Pfizer's version, however, would be specific to SARS-CoV-2 treatment.

Early in the pandemic, existing antivirals, especially protease inhibitors, intrigued scientists.  That's because they'd noticed that HIV patients already taking protease inhibitors for AIDS disease, if they caught COVID, mostly had surprisingly mild cases and unexpected survival rates.  Also, in 2003, an earlier coronavirus — SARS-CoV-1 — responded well to protease inhibitors.  Pfizer explained,

[Parley Baer]

How did you take it?

[LTC.Ret]

I wonder which specific avermectin or milbemycin (avermectins: Abamectin, Doramectin, Emamectin, Eprinomectin, IVERMECTIN, Selamectin; milbemycins: Moxidectin. Milbemycin oxime) Pfizer made one tiny little change in to call their own. Or maybe a combination of any two of the above? Even without a change, if they supply it in any kind of a different pill form or mix they can patent it and cha-ching the daylights out of it for many years.

[John Semmens]

Pfizer Announces “Covicure”

Fresh off its triumph of getting the Food & Drug Administration (FDA) to approve its comirnaty vaccine, Pfizer has announced its success in developing a cure for COVID.

Company spokesman Brad Lyman explained “while we have every confidence that comirnaty will prove invincible against the coronavirus we acknowledge that it may not be possible to vaccinate everyone as often as is needed to maintain immunity. Not wanting to leave the world without a back-up plan, we developed covicure. This oral medication comes in two versions covicure-H and covicure-I.”

“Both of these drugs contain a proprietary blend of vitamins B, C & D, zinc, lactoferrin, melatonin, N-acetyl cysteine (NAC), quercetin, and an alternate secret ingredient—one called ‘H’ and the other called ‘I,’” Lyman said. “Numerous trials of these substances over the past year-and-a-half have demonstrated a very high success rate against the virus. We’re now taking the next logical step of patenting our special blends, which we feel will quickly achieve FDA approval.”

The company estimated that once these products hit the market a two-week course of treatment can be provided at a cost of $5,000 per patient—an amount that Lyman called “very reasonable considering there are no other effective approved alternatives for the treatment of this deadly disease.”

In related news, the American Medical Association, American Pharmacists Association, and American Society of Health-System Pharmacists called for an immediate end to ordering, prescribing, or dispensing ivermectin to prevent or treat COVID-19. The group labeled the numerous reports of the success of this drug in treating the virus in various places including India, Africa, and Peru “anecdotal” and “not compatible with the far more sophisticated medical knowledge and practice in the United States.”

[Apple Pan Dowdy]

Pfizermectin